Study design (if review, criteria of inclusion for studies)
Interventional - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
Participants
Cystic Fibrosis|Hypoestrogenism - 16 Years to 30 Years (Child, Adult)
Interventions
Drug: Transdermal estrogen|Drug: Placebo patch|Drug: Progesterone|Drug: Placebo pill
Outcome measures
Number of potential participants enrolled per month. Rate of screen fails. Study procedure completion rate. Acceptability as determined by participant report. Change in serum estradiol levels (pg/mL). Change in serum procollagen type I intact N-terminal propeptide (P1NP) levels (mcg/L). Change in serum C-terminal telopeptide of type I collagen (CTX-1) levels (pg/mL). Change in lumbar spine bone mineral density assessed by dual-energy x-ray absorptiometry (DXA). Change in quality of life as assessed by Cystic Fibrosis Respiratory Symptom Diary - Chronic Respiratory Infection Symptom Score (CFRSD-CRISS) questionnaire